Brain tumours have a high mortality rate and are the most common solid tumour of childhood. The non-invasive imaging technique, MRS, measures tumour metabolites which can provide additional prognostic information to aid in clinical management. MRS metabolites Glycine, Scyllo-Inositol, NAA and Lipids have been associated with prognosis for pediatric brain tumour patients in a single centre 1.5T study. This study aimed to validate these MRS survival markers in a 3T multicentre setting. In this preliminary study Lipids were validated as a survival marker across childhood brain tumours.